Key facts
- ARMISTICE CAPITAL, LLC filed SCHEDULE 13G for CALIDI BIOTHERAPEUTICS, INC. Common stock, par value $0.0001 per share (CLDI).
- Disclosed ownership: 10%.
- Date of event: 31 Mar 2026.
ARMISTICE CAPITAL, LLC - 31 Mar 2026 SCHEDULE 13G Report for CALIDI BIOTHERAPEUTICS, INC. Common stock, par value $0.0001 per share (CLDI)
- Filing Manager
- ARMISTICE CAPITAL, LLC
- Reporting Manager
- Armistice Capital, LLC
- Symbol
- CLDI
- Shares outstanding
- 11,128,448 shares
- Disclosed Ownership
- 1,111,732 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G
- Filing time
- 15 May 2026, 11:10:35 UTC
- Date of event
- 31 Mar 2026
- Previous filing
- 15 May 2025
- SEC
- View on sec.gov
Key filing fact
ARMISTICE CAPITAL, LLC disclosed 10% ownership in CALIDI BIOTHERAPEUTICS, INC. Common stock, par value $0.0001 per share (CLDI) on 31 Mar 2026.
Change
- Previous schedule filing date: 15 May 2025.
- Current filing was accepted on 15 May 2026, 11:10.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 10% | 1,111,732 | 0 | 1,111,732 | /s/ Steven Boyd | Steven Boyd - Managing Member | |
| Steven Boyd | 10% | 1,111,732 | 0 | 1,111,732 | /s/ Steven Boyd | Steven Boyd |
CIK / CUSIP context first